Trial · NCT00365768
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
NCT00365768, Phase 2, Completed, Columbia University; results first posted 2016-09-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors. Trials, record NCT00365768. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00365768
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
- NCT number
- NCT00365768
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 56 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
- Interventions
- Glutamine, Placebo
- First posted
- 2006-08-17
- Last updated
- 2016-09-09
- Results first posted
- 2016-09-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Vincristine-induced Peripheral Neuropathy | Up to 30 weeks from baseline while on Vincristine treatment | |
| Secondary | Number of Participants With Progression of Neuropathy | 42 days |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Vincristine-induced Peripheral Neuropathy | Up to 30 weeks from baseline while on Vincristine treatment | participants | NUMBER | |
| SECONDARY | Number of Participants With Progression of Neuropathy | 42 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Vincristine-induced Peripheral Neuropathy | Arm I: Glutamine | 24 | participants | ||
| Incidence of Vincristine-induced Peripheral Neuropathy | Arm II: Placebo | 25 | participants | ||
| Number of Participants With Progression of Neuropathy | Arm I: Glutamine | 11 | participants | ||
| Number of Participants With Progression of Neuropathy | Arm II: Placebo | 19 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm I: Glutamine | 24 | |
| Overall Study | STARTED | Arm II: Placebo | 25 | |
| Overall Study | COMPLETED | Arm I: Glutamine | 24 | |
| Overall Study | COMPLETED | Arm II: Placebo | 25 | |
| Overall Study | NOT COMPLETED | Arm I: Glutamine | 0 | |
| Overall Study | NOT COMPLETED | Arm II: Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm I: Glutamine | ||
| Total, all-cause mortality | Arm II | ||
| Total, other adverse events | Arm I: Glutamine | 0 | 24 |
| Total, other adverse events | Arm II | 0 | 25 |
| Total, serious adverse events | Arm I: Glutamine | 0 | 24 |
| Total, serious adverse events | Arm II | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Arm I: Glutamine vs Arm II: Placebo: Incidence of Vincristine-induced Peripheral Neuropathy | Trial comparisons |
| Arm I: Glutamine vs Arm II: Placebo: Number of Participants With Progression of Neuropathy | Trial comparisons |
| Arm I: Glutamine vs Arm II: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00365768
GET https://conductscience.org/api/trials/v1/NCT00365768/registered